Published in Biotech Business Week, February 26th, 2007
The company established second quarter revenue guidance of $345 to $355 million with EPS, excluding any restructuring charges, in the range of $0.15 to $0.19.
Plexus revised its full fiscal year revenue growth target to 8% to 12% over fiscal 2006.
Dean Foate, president and CEO, commented, "From a revenue perspective, in Q1 we achieved slightly better than expected performance in our Medical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.